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Background: Hamartomatous polyposis syndromes (HPS) are inherited conditions associated with high cancer risk.
They include the Peutz-Jeghers and the PTEN hamartoma tumor syndromes, which are caused by mutations in the
LKB1 and PTEN genes, respectively. Estimation of cancer risk is crucial in order to optimize surveillance, but no
prognostic markers are currently available for these conditions. Our study relies on a ‘signal transduction’ hypothesis
based on the crosstalk between LKB1/AMPK and PI3K/PTEN/Akt signaling at the level of the tumor suppressor
protein FoxO3A. Interestingly, the FOXO3A rs2802292 G-allele was shown to be associated with longevity, reduced
risk of aging-related diseases and increased expression of FoxO3A mRNA.
Methods: We typed rs2802292 in 150 HPS unrelated patients and characterized the expression of FoxO3A by
quantitative PCR and immunoblot analysis in human intestinal cell lines.
Results: We found a significantly higher risk for malignancies in females and TT genotype carriers compared to
patients having at least one G-allele. Subgroup analysis for each HPS syndrome revealed a G-allele-associated
beneficial effect on cancer risk occurring mainly in males. Molecular characterization of human intestinal cell lines
showed that the G-allele significantly correlated with increased basal expression of FoxO3A mRNA and protein.
Conclusion: Our results suggest an inverse correlation between the protective allele (G) copy number and cancer
risk, and might be useful to optimize surveillance in HPS patients. Further investigations are needed to confirm our
hypothesis and to ascertain whether differences in therapeutic response exist across genotypes.
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Hamartomatous polyposis syndromes (HPS) - Peutz-
Jeghers syndrome (PJS), PTEN hamartoma tumor syn-
drome (PHTS) and juvenile polyposis syndrome (JPS) - are
inherited conditions showing hamartomatous polyp hist-
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unless otherwise stated.Hamartomatous polyps originate from uncontrolled pro-
liferation of stromal cells and represent a small fraction of
all polyps arising in the GI tract [1].
PJS is an autosomal dominant disease with an estimated
prevalence of 1/8,300 to 1/200,000, and is characterized by
the presence of mucocutaneous pigmentation, hamarto-
matous polyps and an increased risk of cancer at different
sites (breast, GI tract, gynecological tumors) [2]. PJS is
caused by mutations in the LKB1 tumor suppressor gene,
which encodes a serine/threonine kinase [3].
PHTS has a prevalence estimate of 1/200,000 and com-
prises a group of phenotypically diverse rare autosomaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Our study is based on a ‘signal transduction’
hypothesis, which relies on the crosstalk between LKB1/AMPK
and PI3K/PTEN/Akt signaling at the level of FoxO3A. In
particular, LKB1 activates AMPK, which in turn activates FoxO3A,
while PTEN inhibits Akt, which in turn inhibits FoxO3A.
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and Bannayan-Riley Ruvalcaba syndrome (BRRS) [4].
These are caused by germline mutations in the PTEN
tumor suppressor gene, which encodes a phosphatase.
Hamartomatous tumors can affect any organ, namely
skin, mucosal membranes, GI tract and other organs in
CS, and GI tract in BRRS, which is also associated with
macrocephaly, lipomatosis, and pigmented macules of
the glans penis. PHTS shows an increased risk of malig-
nancies of the breast, colorectum, thyroid, kidney and
endometrium [5].
Several reports estimated cancer risk in HPS. PJS and
PHTS patients show a time-dependent high risk of ma-
lignancies, with females displaying a significantly higher
risk than males mainly due to the occurrence of breast
and gynecological tumors [2,4].
Estimation of cancer risk is crucial in order to imple-
ment risk-reducing measures, including intensive sur-
veillance, lifestyle changes, chemoprevention or even
prophylactic surgery. However, there is currently no
available marker that can predict which HPS patients
will develop a malignancy and the age at which surveil-
lance should be started. Recently, genetic modifiers have
been shown to play a role in determining cancer risk in
other mendelian tumor syndromes, such as BRCA1/2-
related breast and ovarian cancer, [6,7] and SNP geno-
typing could be of help in identifying a ‘modifier locus’
to predict the risk of cancer in HPS patients.
Our study is based on a ‘signal transduction’ hypoth-
esis, which relies on the crosstalk between LKB1/AMPK
and PI3K/PTEN/Akt signaling at the level of FoxO3A
(Figure 1). In particular, LKB1 activates AMPK, which in
turn activates FoxO3A, while PTEN inhibits Akt, which
in turn inhibits FoxO3A [8]. Recently, it was found that
the FOXO3A locus strongly correlates with the longevity
phenotype in genetically diverse groups of European and
Asian descent [9-13]. Of note, the FoxO3A rs2802292
G-allele (minor allele count/MAF = 0.449/978) [14] was
shown to be associated with longevity in all populations
tested, [9-13] and its copy number correlated with re-
duced frequency of aging-related diseases, including can-
cer, in centenarians [9]. At the molecular level, the
rs2802292 G-allele displayed significant correlation with
increased basal expression of FoxO3A mRNA in muscle
biopsies of twins, suggesting that the second intron of
the FOXO3A locus, which contains the rs2802292 SNP,
may act as a regulatory sequence [15].
These data suggest that the rs2802292 G-allele could
enhance the well-known metabolic and anti-aging activ-
ities of FOXO3A by increasing gene expression. Indeed,
FoxO3A plays a role in proliferation/arrest, survival/
death, metabolism and autophagy, and has been impli-
cated in tumor suppression, regulation of energy metab-
olism and development in a number of tissues [8]. Allthese functions are mediated by the finely tuned activation
of a coordinated transcriptional program encompassing
genes involved in cell cycle, metabolism, autophagy, stress
resistance and cell death [8].
To ascertain whether the positive effect of the rs2802292
G-allele on FoxO3A activity could counteract the det-
rimental effects of imbalanced AMPK/Akt signals on
transformation and cancer progression in PJS and PHTS
tissues, we typed this polymorphism in a group of unre-
lated patients previously characterized for LKB1 or PTEN
mutations.
Methods
Participants
The FoxO3A rs2802292 SNP was analyzed in 150 HPS
unrelated patients with identified mutations in the PTEN
(84 patients) or LKB1 (66 patients) genes. PTEN or LKB1
mutation carriers were recruited through various Italian
cancer genetics clinics and fulfilled the diagnostic clinical
criteria for PJS or PHTS, [16,17] and/or they were carriers
of the familial disease-causing mutation. We obtained par-
ticipants’ informed consent approved by the local ethical
committees (AOU Policlinico, 70124 Bari, Italy; Meyer
University Hospital, 50139 Florence, Italy) for publication
of the dataset at recruitment into the study in compliance
with international and national data protection laws. The
dataset is fully anonymous, as it does not contain any
direct or indirect identifier, thus respecting participants’
rights to privacy and protecting their identity.
Table 1 Tumor number and location in PJS and
PHTS patients
PHTS patients* PJS patients**
Thyroid 4 1
Breast 3 4
Gynecological tract 2 10
Kidney 2 0
Gastrointestinal tract 1 3
CNS 1 0
Other 1 0
Total 14 18
*2 patients with multiple tumors.
**3 patients with multiple tumors.
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HT-29, Caco-2, LS174T, HCT-116 cells (all from ATCC)
were grown in DMEM supplemented with 10% FBS
(HT-29, LS174T and HCT-116) or 20% FBS (Caco-2),
100 IU/ml penicillin and 100 μg/ml streptomycin in a
humidified incubator at 37°C and 5% CO2 avoiding con-
fluence at any time.
Genotyping
Genomic DNA from peripheral blood and cell lines was
extracted using QIAsymphony SP/AS instruments (QIA-
GEN) according to the manufacturer’s protocol and
quantified on a NanoDROP 2000 spectrophotometer
(Thermo Scientific). PCRs were carried out in 25 μl re-
action mixtures containing 50 ng of genomic DNA, 1X
PCR Buffer (Tris–HCl, (NH4)2SO4, 15 mM MgCl2;
pH 8.7), 200 μM dNTPs and 0.5 U HotStarTaq DNA
Polimerase (QIAGEN) and the following primers (10
pmol each): FoxO3A rs2802292g/t Fw, cagcttctgagtgaca-
gagtg and FoxO3A rs2802292g/t Rw, ttcttccctagagagcag-
cag. PCR amplification cycles were carried out at 95°C
for 15 min followed by 29 cycles of denaturation at 94°C
for 1 min, annealing at 60°C for 1 min and extension at
72°C for 1 min, and then a final extension at 72°C for
10 min on a GeneAmp PCR System 9700 thermocycler
(Applied Biosystems). 5 μl of the amplified products
were loaded onto 2% Agarose Standard Low EEO (AB
Analitica) in 0.5X TBE and visualized using GelRedTM
(Biotium, Hayward, CA). Sequencing products were
purified by use of the DyeEx™ 2.0 Spin Kit (QIAGEN,
Milan, Italy) and sequenced on an ABI PRISM 310 Gen-
etic Analyzer (Applied Biosystems).
Quantitative real time PCR
Total RNAs were extracted using TRI Reagent (Sigma).
Samples were treated with DNase-1 (Ambion) and
retro-transcribed using the High Capacity DNA Archive
Kit (Applied Biosystems). PCRs were carried out using
the SYBR Green PCR Master Mix on an ABI 7500HT
machine (Applied Biosystems). Relative quantification
was done using the ddCT (Pfaffl) method. Primer se-
quences are available upon request.
Immunoblotting analysis
Immunoblotting analyses were performed according to
Cell Signaling’s instructions. Briefly, cells were homoge-
nized in 1X lysis buffer (50 mM Tris–HCl pH 7.4; 5 mM
EDTA; 250 mM NaCl; 0.1% Triton X-100) supplemented
with protease and phosphatase inhibitors (1 mM PMSF;
1.5 μM pepstatin A; 2 μM leupeptin; 10 μg/ml aprotinin,
5 mM NaF; 1 mM Na3VO4). 15 to 20 μg of protein ex-
tracts from each sample were denatured in 5× Laemmli
sample buffer and loaded into an SDS-polyacrylamide gel
for western blot analysis. Western blots were performedusing anti-β-Actin (Sigma) and anti-FoxO3A (Cell Signal-
ing). Western blots were developed with the ECL-plus
chemiluminescence reagent (GE Healthcare) as per manu-
facturer’s instructions.
Statistical methods
Patient characteristics were reported as medians and
interquartile range (IR), and frequency and percent-
ages, for continuous and categorical variables, respect-
ively. Characteristics were also stratified according to
the presence of malignant tumors, mutation type and
genotype, and compared using Pearson’s χ2 and Mann–
Whitney U tests for categorical and continuous vari-
ables, respectively. To account for potential confound-
ing, presence of malignant tumors was analysed with
multivariate logistic regression models and the follow-
ing covariates were included: gender, age at diagnosis
(in years) and genotype (TT and XG). Results were re-
ported as odds ratios (ORs) along with their 95% con-
fidence intervals (95% CI). Adjusted risks for each
variable employed in the models were also estimated.
Two-sided p-values < 0.05 were considered statistically
significant. All statistical analyses were performed
using SAS Statistical Package version 9.3 (SAS Insti-
tute, Cary, NC).
Results
A total of 150 patients were analyzed. Median age at
diagnosis was 18 (IR 1–77) years, females were 44.7%,
and patients with LKB1 and PTEN mutations were 56%
and 44%, respectively. Prevalence of the rs2802292 G-allele
was 45.3%, which is consistent with the MAF previously
described for the general population [14].
Overall cancer risk for our sample was 19.7%. Patient
characteristics according to the presence of malignancies
(see Table 1 for cancer locations) are shown in Table 2.
Patients with and without cancer tended to differ sig-
nificantly in terms of gender, age at diagnosis and TT
Table 2 Patients characteristics according to the presence
of malignant tumors
Malignant tumors
Variable Category No Yes p-value
n 106 26
Age 31.00
(3.00-78.00)
48.00
(13.00-85.00)
0.001
Age at diagnosis 17.00
(1.00-72.00)
24.50
(5.00-77.00)
0.0421
Genotype GG 28 (26.42) 5 (19.23) 0.1062
TG 48 (45.28) 8 (30.77)
TT 30 (28.30) 13 (50.00)
Genotype (2 levels) XG 76 (71.70) 13 (50.00) 0.0344
TT 30 (28.30) 13 (50.00)
Mutation LKB1 56 (52.83) 16 (61.54) 0.4242
PTEN 50 (47.17) 10 (38.46)
Sex F 39 (36.79) 17 (65.38) 0.0082
M 67 (63.21) 9 (34.62)
Benign tumors No 27 (25.47) 3 (11.54) 0.1287
Yes 79 (74.53) 23 (88.46)
G.I. benign tumors No 43 (40.57) 4 (15.38) 0.0163
Yes 63 (59.43) 22 (84.62)
G.I. malignant tumors No 106 (100.00) 21 (80.77) <0.0001
Yes 0 (0.00) 5 (19.23)
Data are expressed as medians and interquartile range, and frequency and
percentages, for continuous and categorical variables, respectively. P values
refer to Pearson’s χ2 and Mann–Whitney U tests for categorical and continuous
variables, respectively.
Table 4 Multivariate logistic regression model for the
presence of malignant tumors in PJS patients
Parameter Label OR (95% CI) P value
Sex M VS F 0.23 (0.06-0.94) 0.0407
Genotype (2 levels) TT VS XG 2.82 (0.74-10.71) 0.1285
Age at diagnosis 1.02 (0.97-1.06) 0.4816
The model is adjusted for gender, age at diagnosis (in years) and genotype
(2 levels).
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diagnosis) adjusted analyses are provided in Table 3. A
significantly higher risk of malignancies was found for
females (OR 3.33, 95% CI 1.32-8.33; p: 0.011) and TT
genotype carriers compared to patients having at least
one G-allele (XG) (OR 2.53, 95% CI 1.01-6.34; p:
0.048). This genotype-associated risk increase was
slightly greater in PJS (OR 2.82 95% CI 0.74-10.81; p:
0.128) than in PHTS (OR 2.14 95% CI 0.46-9.93; p:
0.332) (Tables 4 and 5). Furthermore, females carrying
at least one G-allele (XG) showed a cancer risk of 28%Table 3 Multivariate logistic regression model for the
presence of malignant tumors
Parameter Label OR (95% CI) P value
Sex M VS F 0.30 (0.12-0.76) 0.0114
Genotype (2 levels) TT VS XG 2.53 (1.01-6.34) 0.0484
Age at diagnosis 1.02 (0.99-1.04) 0.1797
Model is adjusted for gender, age at diagnosis (in years) and genotype
(2 levels).(95% CI 15-44%), which increased to 35% (95% CI 17-
58%) for TT females. Of note, only 6% (95% CI 2-16%)
of XG males had cancer, while the percentage rose to
25% (95% CI 12-47%) for TT male carriers. Subgroup
analysis for each syndrome revealed that the G-allele-
associated beneficial effect on cancer risk occurs
mainly in HPS males [PJS males with cancer: XG 7%
(95% CI 1-27%) vs TT 22% (95% CI 5-62%); PHTS
males with cancer: XG 4% (95% CI 0-27%) vs TT 28%
(95% CI 9-59%)]. Of note, PJS females carrying the TT
genotype were the subgroup with the highest cancer
rate [49% (95% CI 21–77)]. This latter result suggests
an inverse correlation between the copy number of the
protective allele (G) and the risk of cancer, which
would be consistent with the reduced frequency of
aging-related diseases, including cancer, observed in
centenarians [9].
To get insight into the molecular mechanism possibly
explaining the beneficial effect of the rs2802292 G-
allele, we measured FoxO3A mRNA and protein levels
in human intestinal cell lines. Based on our results, cells
carrying the GG genotype (HCT-116, Caco-2) showed
significantly higher expression of FoxO3A mRNA and
protein compared to cells with the TT genotype (HT-
29, LS174T) (Figure 2). These data are in agreement
with the analysis performed in muscle biopsies of 190
twins indicating that the rs2802292 G-allele was asso-
ciated with increased basal expression of FoxO3A
mRNA [15].
Discussion
None of the other parameters (mutation type, presence
of benign tumors and age at diagnosis) significantlyTable 5 Multivariate logistic regression model for the
presence of malignant tumors in PHTS patients
Parameter Label OR (95% CI) P value
Sex M VS F 0.52 (0.11-2.42) 0.4038
Genotype (2 levels) TT VS XG 2.14 (0.46-9.93) 0.3317
Age at diagnosis 1.02 (0.99-1.06) 0.1917
The model is adjusted for gender, age at diagnosis (in years) and genotype
(2 levels).
Figure 2 GG genotype is associated with increased expression of FoxO3A both at the mRNA and protein level. HT-29, LS174T, HCT-116
and Caco-2 human intestinal cells were typed for the rs2802292 polymorphism and then analyzed by quantitative real-time PCR (A) and immunoblotting
(B) to measure FoxO3A mRNA and protein expression. β-Actin was used as a loading control.
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of high interest because various research groups
throughout the world reported cancer risk estimates of
up to and over 80% for HPS patients by age 70 [2,4].
Based on our data, we speculate that HPS subjects car-
rying a GG genotype (which supposedly make up
around 20% of the overall HPS population) are less
likely to develop cancer or tend to be affected at an ad-
vanced age, while TT subjects develop malignancies
earlier in life and TG individuals show an intermediate
phenotype. Indeed, our ‘signal transduction’ hypothesis,
which proposed FoxO3A as the crossroad of the HPS
pathways LKB1/AMPK and PI3K/PTEN/Akt (Figure 1), is
supported by our finding that the GG genotype is associ-
ated with increased expression of FoxO3A both at the
mRNA and protein level (Figure 2). Regulation of FoxO3A
protein expression and localization is crucial for cancer
progression and treatment. Indeed, FoxO3A is downregu-
lated in several neoplasms, [18] and inducing increased
FoxO3A expression levels is often sufficient to trigger its
transcriptional program in cancer cells leading to cell cycle
arrest, metabolic regulation and cell death [19].
Conclusions
Given the relatively small sample size and the cross-
sectional design of the study, we cannot exclude the
possibility of uncontrolled biases and residual con-
founding, which is why this hypothesis needs to be
confirmed on a higher number of patients and on
different populations, as well as through prospective
studies. These investigations will also be crucial to as-
certain whether differences exist in terms of thera-
peutic response across genotypes and if mortality is
influenced by the rs2802292 allele in HPS subjects. In-
deed, FoxO3A, which is a well-known tumor suppressor
gene, has emerged as a key downstream effector of vari-
ous drugs used in tumor treatments, such as p38inhibitors, cisplatin, paclitaxel, doxorubicin, imatinib,
PI3K-Akt inhibitors, EGFR/HER2 inhibitors, and ioniz-
ing radiation [8].
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